Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

Published:2020-07 Issue:16 Volume:9 Page:5819-5826
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Zhou Xiang¹,Steinhardt Maximilian J.¹,Grathwohl Denise¹,Meckel Katharina¹,Nickel Katharina¹,Leicht Hans‐Benno¹,Krummenast Franziska¹,Einsele Hermann¹,Rasche Leo¹^ORCID,Kortüm Klaus M.¹

Affiliation:

1. Department of Internal Medicine II University Hospital of Würzburg Würzburg Germany

Funder

Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg

Deutsche Krebshilfe

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3209

Reference18 articles.

1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

2. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

3. Guidelines for determination of the number of prior lines of therapy in multiple myeloma

4. Clinical and biologic implications of recurrent genomic aberrations in myeloma

5. Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma;Hematological Oncology;2023-01-26

2. Bim downregulation by activation of NF-κB p65, Akt, and ERK1/2 is associated with adriamycin and dexamethasone resistance in multiple myeloma cells;Clinical and Experimental Medicine;2022-11-30

3. Evaluation of Cardiac Function before and after PAD Regimen in Patients with Multiple Myeloma by Three-Dimensional Speckle Tracking Imaging;Journal of Healthcare Engineering;2022-01-27

4. Salvage therapy with “Dara‐KDT‐P(A)CE” in heavily pretreated, high‐risk, proliferative, relapsed/refractory multiple myeloma;Hematological Oncology;2021-11-22

5. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond;Journal of Hematology & Oncology;2021-07-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3